Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MK0364 in Obese Patients
NCT00109148Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2004
- Primary completion
- Jan 2005
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Drugs
- taranabant
- Conditions
- obesity
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing MK0364 with Placebo (2 arms). Primary endpoint: Change in Body Weight at 24 weeks. Started Jul 2004; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
MK0364
Taranabant
Placebo
Placebo
03
Who it enrols
Obese patients (considerably overweight) based on body mass index, excluding those with serious or unstable medical conditions.
04
Endpoints
Primary
Change in Body Weight
Secondary
Adverse Events
Beyond the preview
Go deeper on NCT00109148.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109148.